Axis-Shield has received notice of approval of its US patent application governing the measuring methodology for HbA1c within the Afinion cassette for detection of this important marker of diabetic patient compliance.
Subscribe to our email newsletter
The patent protects technology which improves HbA1c stability, precision and accuracy and has resulted in a longer product shelf-life with improved performance. The invention may also have utility for the NycoCard product for the same marker.
Ian Gilham, Axis-Shield CEO, said: “We are developing a strong franchise for measuring HbA1c in diabetes through Afinion and NycoCard at the point-of-care and on the Abbott AxSYM analyser in the hospital laboratory. We are pleased to have been granted this patent as part of our program to protect our innovative technology in the expanding near-patient testing marketplace.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.